acadia-pharm.com

Excerpted from the website: About Us ACADIA Pharmaceuticals (Nasdaq:ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. We currently have four programs in clinical development and several additional programs in preclinical and discovery stages directed at large unmet medical needs and major commercial markets. Our three Phase II-stage clinical programs, for which we have retained worldwide commercialization rights, are ACP-103 for treatment-induced dysfunction in Parkinson's disease, ACP-103 as an adjunctive therapy for schizophrenia, and ACP-104 for treatment of schizophrenia. We also have a neuropathic pain program in Phase II clinical trials in collaboration with Allergan, Inc.

This article uses content from http://www.AboutUs.org